BioAtla, Inc. (BCAB)

Market Cap	75.90M
Revenue (ttm)	11.00M
Net Income (ttm)	-81.82M
Shares Out	48.35M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,557,504
Open	1.370
Previous Close	1.390
Day's Range	1.370 - 1.900
52-Week Range	1.140 - 4.020
Beta	1.02
Analysts	Buy
Price Target	5.00 (+218.47%)
Earnings Date	Nov 7, 2024

About BCAB

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of mela...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2020
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: BCAB
• Website: https://www.bioatla.com

Analyst Forecast

According to 2 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 218.47% from the latest price.

Price Target

$5.0

(218.47% upside)

Analyst Consensus: Buy